Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00108108
Status:
TERMINATED
Last Update Posted:
2012-10-01
First Post:
2005-04-14
Brief Title:
Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia CLL That is Relapsed or Non-responsive to Prior Fludaribine Therapy
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
An Open-labelMulti-center Phase lll Study of Anti-CD40 Monoclonal Antibody HCD122 Administered Intravenously to Subjects With Advanced Chronic Lymphocytic Leukemia That is Refractory or Relapsed After at Least One Previous Fludarabine-containing Chemotherapy Regimen
Status:
TERMINATED
Status Verified Date:
2012-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Slow enrollment and minimal preliminary biological and clinical efficacy
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the highest tolerated dose safety and activity of HCD122 in patients with chronic lymphocytic leukemia who are relapsed after receiving prior treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None